Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Castle Biosciences (CSTL) Preferred Shares Issued (2018 - 2019)

Castle Biosciences' Preferred Shares Issued history spans 2 years, with the latest figure at $49000.0 for Q3 2019.

On a quarterly basis, Preferred Shares Issued rose 699900.0% to $49000.0 in Q3 2019 year-over-year; TTM through Dec 2019 was $49493.0, a N/A change, with the full-year FY2019 number at $49000.0, down 99.53% from a year prior.
Preferred Shares Issued hit $49000.0 in Q3 2019 for Castle Biosciences, up from $486.0 in the prior quarter.
Over the last five years, Preferred Shares Issued for CSTL hit a ceiling of $49000.0 in Q3 2019 and a floor of $7.0 in Q3 2018.